The study included 52 patients with Hodgkin's disease, 32 males and 20 females, whose ages ranged from 3 to 36 years (34 under and 18 over 15 years). All patients were carefully staged, and lymph-node biopsies were taken for histopathological examination. HLA phenotype determinations were carried out, and the frequencies were statistically compared with those of normal Egyptian controls. We followed the patients for 3 years to monitor the effect of therapy. In order to determine the prognostic value of patients' characteristics (age, stage, histologic pattern and HLA phenotypes), statistical analysis and retrospective stratification studies were performed. The frequency of HLA-AI was significantly increased in our patients. The relative risk showed that persons carrying the AI antigen are 6 times more susceptible than those lacking it. There was no significant difference in the frequency of AI antigen in relation to the histopathologic subtypes. Furthermore, the results revealed a prognostic value of the HLA marker. In conclusion, we suggest that chemotherapy should be added to radiotherapy of marker-positive patients at any stage.
Blood lymphocytes from six unrelated patients with neurofibromatosis and three normal controls were examined for their response to different doses (0, 75, 150, 300, 400 rad) of x‐radiation, as measured by chromosome aberrations (gaps, breaks, dicentrics, centric rings, acentric ring, fragments, and minutes). Cytogenetic studies on phytohemagglutinin‐stimulated cells revealed chromosomal instability in the neurofibromatosis lymphocytes as shown by the significant increase in the incidence of gaps, breaks and dicentrics. This increase paralleled the increase in the dose of irradiation. The significance of these findings is discussed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.